TY - JOUR
T1 - Overlapping of DRESS and Stevens-Johnson syndrome due to first-line antituberculosis drugs
T2 - a case report
AU - Morán-Mariños, Cristian
AU - Llanos-Tejada, Felix
AU - Huamani-Llantoy, Rebeca
AU - Bernal-Turpo, Capriny
AU - López-Pilco, Kimberly
AU - Ventura-Leon, Alex
AU - Casanova-Mendoza, Renato
N1 - Publisher Copyright:
© The Author(s), 2025.
PY - 2025/1/1
Y1 - 2025/1/1
N2 - The overlap of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and Stevens-Johnson syndrome (SJS) caused by antituberculosis drugs represents an extremely rare event. This situation can manifest between 2 and 8 weeks after the first exposure to the medication. The overlap of these conditions can lead to atypical clinical manifestations, thus complicating the early diagnosis and the implementation of early treatment. This report describes the case of a patient who developed the DRESS/SJS overlap 35 days after starting antituberculosis treatment. The patient experienced severe skin and systemic involvement, a situation that required her admission and monitoring in the intensive care unit. From our experience with this case, we conclude the importance of an accurate and timely diagnosis using validated scoring systems such as RegiSCAR to confirm the clinical diagnosis of DRESS/SJS and ALDEN to assess the likelihood of drug causality. Timely intervention with corticosteroids plays a key role in moderating the exaggerated immune response, helping to alleviate dermatological symptoms and prevent long-term organ damage. In addition, the availability of safe therapeutic alternatives for tuberculosis treatment allows for more effective and safer management in these patients.
AB - The overlap of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and Stevens-Johnson syndrome (SJS) caused by antituberculosis drugs represents an extremely rare event. This situation can manifest between 2 and 8 weeks after the first exposure to the medication. The overlap of these conditions can lead to atypical clinical manifestations, thus complicating the early diagnosis and the implementation of early treatment. This report describes the case of a patient who developed the DRESS/SJS overlap 35 days after starting antituberculosis treatment. The patient experienced severe skin and systemic involvement, a situation that required her admission and monitoring in the intensive care unit. From our experience with this case, we conclude the importance of an accurate and timely diagnosis using validated scoring systems such as RegiSCAR to confirm the clinical diagnosis of DRESS/SJS and ALDEN to assess the likelihood of drug causality. Timely intervention with corticosteroids plays a key role in moderating the exaggerated immune response, helping to alleviate dermatological symptoms and prevent long-term organ damage. In addition, the availability of safe therapeutic alternatives for tuberculosis treatment allows for more effective and safer management in these patients.
KW - antitubercular agents
KW - drug hypersensitivity syndrome
KW - hypersensitivity
KW - Stevens-Johnson syndrome
KW - tuberculosis
UR - http://www.scopus.com/inward/record.url?scp=85216774295&partnerID=8YFLogxK
U2 - 10.1177/20420986241312484
DO - 10.1177/20420986241312484
M3 - Artículo
AN - SCOPUS:85216774295
SN - 2042-0986
VL - 16
JO - Therapeutic Advances in Drug Safety
JF - Therapeutic Advances in Drug Safety
ER -